Applications in target ID and validation

Russell Publishing Ltd
Court Lodge
Hogtrough Hill
Brasted
Kent TN16 1NU. UK
Registered in England
No. 2709148
Registered office as above.
VAT No. GB 577 897847

You are here: Home » Functional Genomics » Applications in target ID and validation

publication date: Nov 11, 2005

RNAi technology provides the ‘loss of function’ approach, which has been widely used in the last couple of years for analysis of gene function, and in drug discovery for identification and validation of potential drug target candidates. This technology is now widely applied for functional screens in order to identify disease associated signals and targets whose specific inhibition could potentially result in a curative effect for treatment of complex human diseases. The focus of such screens is evolving more towards druggable gene families rather than genome wide approaches – the latter being expensive, complex and sometimes confusing.

Sorry, this page is available to members only.

If you have not registered with us yet, why not register today for FREE and receive exclusive online access. Interested in receiving European Pharmaceutical Review in print? Subscribe today and guarantee the next six issues delivered direct to your desk, plus gain exclusive access online.

Why should I register online with European Pharmaceutical Review?

You will receive . . .

* Up to date information on all latest technologies in drug development and manufacturing

* Exciting new features, interviews, updates and profiles

* All latest developments, news and innovations

* Information on projects that your industry colleagues are involved in

* Exclusive access our back issue archive

Click here to join